Biohaven Stock Climbs on Favorable Trade Secret Ruling and Pipeline Outlook

Biohaven Pharmaceutical stock rose on Monday, buoyed by the lingering effect of a significant legal victory that affirmed its intellectual property rights and by investor anticipation of several upcoming clinical trial milestones.

Legal Victory Secures Key Platform

A federal jury in Delaware last week found that Avilar Therapeutics and RA Capital Management had willfully and maliciously misappropriated a trade secret from Yale University, according to a public announcement from Biohaven. The company, along with Yale, was awarded a combined $4 million in damages following the trial.

The verdict is significant for investors as it validates Biohaven's licensed rights to the MODA targeted protein degradation platform. This technology is a cornerstone of the company's extracellular protein degrader programs, which include potential treatments like BHV-1300 for Graves’ disease and BHV-1400 for IgA nephropathy.

Upcoming Clinical Catalysts

Beyond the favorable court ruling, investor focus is also on Biohaven's pipeline, with several key data readouts expected in the second half of 2026. These potential catalysts are helping to drive positive sentiment around the stock.

Ad

Key upcoming milestones include:

• Topline results from the RISE3 pivotal Phase 2/3 study of opakalim, a selective Kv7.2/7.3 channel activator being evaluated for epilepsy.
• Data from the Phase 2 trial of taldefgrobep alfa, a candidate for treating obesity.

Market Performance

In afternoon trading, Biohaven shares (BHVN) were up 2.1% to $14.62. The stock's advance occurred against a mixed broader market, where the Dow Jones Industrial Average posted a modest gain while the S&P 500 was flat, allowing company-specific factors to drive performance. The stock remains well above its 52-week low of $7.48, though still below its peak of $18.57.